What is Tepezza?
Tepezza is a medication used for the treatment of thyroid eye disease, also known as Graves' ophthalmopathy. The condition affects the tissues around the eyes, leading to swelling, redness, and often protrusion of the eyes. Tepezza is the first FDA-approved drug for this condition and has been shown to be effective in reducing the severity and progression of symptoms.
The drug is administered through an eight infusion treatment course, with each infusion lasting about an hour. The recommended dose is 10 mg/kg body weight, and the infusions are administered every three weeks. The medication works by targeting IGF-1R, a protein that is responsible for the inflammation and tissue deposition that causes the symptoms of thyroid eye disease.
Tepezza has been shown to be effective in clinical trials, with patients experiencing a significant reduction in their symptoms, including proptosis (eye protrusion), inflammation, and diplopia (double vision). In fact, the drug has been shown to reduce proptosis alone by 2 mm or more in 71% of patients treated.
While Tepezza is considered safe, it is not without side effects. The most common side effects seen in clinical trials include muscle spasms, nausea, and diarrhea. More serious side effects, such as liver injury and stroke, have been reported but are rare.
Despite its potential side effects, Tepezza offers hope to those suffering from thyroid eye disease. The drug has been shown to be effective in reducing the severity and progression of symptoms, allowing patients to enjoy a better quality of life. It is important to note, however, that Tepezza should only be administered by a healthcare professional and that patients should be monitored for any potential side effects.
Frequently Asked Questions about tepezza
Each vial contains 500 milligrams (mg) of the active drug, teprotumumab. Your healthcare professional will use the powder in the vial to make a solution. Then, they'll give the Tepezza solution to you as an intravenous (IV) infusion. (With an IV infusion, the drug is given into your vein over a period of time.)
Unlike other medicines, TEPEZZA treats the cause of T-E-D, not just the symptoms. TEPEZZA is designed to bind to the switch and block it from turning on. Since TEPEZZA blocks the switches so they cannot turn on, swelling of the muscle and fat tissue goes down.
TEPEZZA is a drug for the treatment of thyroid eye disease. Thyroid eye disease is a rare, autoimmune disease characterized by proptosis (a condition where the eyes are pushed forward and bulge outward) leading to eye pain, double vision and difficulty closing the eyelid.
It is a monoclonal antibody although it was initially developed in collaboration with Genmab and Roche for the treatment of the tumour, but later it was investigated by River Vision Development Corporation and Horizon Therapeutics for its ophthalmic use.
Since Tepezza is a biologic drug, it can't have a generic version. This is because biologics are made from living cells and can't be replicated exactly. Instead, it's possible for biologic drugs to have biosimilar versions. Biosimilars are just as safe and effective as the original biologic but often cost less.
Generic Name: teprotumumab-trbw
This medication is used to treat thyroid eye disease, also known as Graves' eye disease. Teprotumumab belongs to a class of drugs known as monoclonal antibodies.
Intravenous Powder For Injection
| Quantity | Per unit | Price |
|---|
| 1 | $16,301.09 | $16,301.09 |
Official answer. No, Tepezza is not used for chemotherapy or to treat any form of cancer.
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration.
Intravenous Powder For Injection
| Quantity | Per unit | Price |
|---|
| 1 | $16,301.09 | $16,301.09 |
TEPEZZA reduces eye bulging and double vision. It also improves the signs and symptoms of Thyroid Eye Disease (TED), including eye pain, redness, and swelling. TEPEZZA is a prescription medicine used to treat TED.
The cost for Tepezza intravenous powder for injection trbw 500 mg is around $16,301 for a supply of 1 powder for injection, depending on the pharmacy you visit.
TEPEZZA is currently only approved by the United States Food and Drug Administration (FDA) for the treatment of TED. It is not currently approved by regulatory authorities in any country other than the United States.
Johnson & Johnson initially tapped Catalent in April to reserve fill-finish capacity at its Bloomington, Indiana, plant - where Tepezza is made - before signing on the CDMO's Anagni, Italy facility for additional production work in July.
The most common side effects of TEPEZZA include muscle cramps or spasms, nausea, hair loss, diarrhea, feeling tired, high blood sugar, hearing problems, taste changes, headache, dry skin, weight loss, nail problems, and changes in menstruation. This is not a complete list of all possible side effects.
